BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, Gardenal R, Dal Mas M, Casarin P, Zanette G, Miranda C. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009; 15(20): 2506-2511 [PMID: 19469001 DOI: 10.3748/wjg.15.2506]
URL: https://www.wjgnet.com/1007-9327/full/v15/i20/2506.htm
Number Citing Articles
1
Takumi Kawaguchi, Eitaro Taniguchi, Minoru Itou, Masahiro Sakata, Shuji Sumie, Michio Sata. Insulin resistance and chronic liver diseaseWorld Journal of Hepatology 2011; 3(5): 99-107 doi: 10.4254/wjh.v3.i5.99
2
Giulio Marchesini, Gabriele Forlani, Roberto J. Groszmann, Yasuko Iwakiri, Tamar H. Taddei. Diabetes and hepatocellular cancer risk: Not only a matter of hyperglycemiaHepatology 2012; 55(4): 1298 doi: 10.1002/hep.25646
3
Laura Pimpin, Helena Cortez-Pinto, Francesco Negro, Emily Corbould, Jeffrey V. Lazarus, Laura Webber, Nick Sheron. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policiesJournal of Hepatology 2018; 69(3): 718 doi: 10.1016/j.jhep.2018.05.011
4
Samy Suissa, Laurent Azoulay. Metformin and the Risk of CancerDiabetes Care 2012; 35(12): 2665 doi: 10.2337/dc12-0788
5
Marion Donnier-Maréchal, Sébastien Vidal. Glycogen phosphorylase inhibitors: a patent review (2013 - 2015)Expert Opinion on Therapeutic Patents 2016; 26(2): 199 doi: 10.1517/13543776.2016.1131268
6
Dana J. Herrigel, Rebecca A. Moss. Diabetes Mellitus as a Novel Risk Factor for Gastrointestinal MalignanciesPostgraduate Medicine 2014; 126(6): 106 doi: 10.3810/pgm.2014.10.2825
7
Sara Salehi Hammerstad, Shira Frankel Grock, Hanna J. Lee, Alia Hasham, Nina Sundaram, Yaron Tomer. Diabetes and Hepatitis C: A Two-Way AssociationFrontiers in Endocrinology 2015; 6 doi: 10.3389/fendo.2015.00134
8
Hiroshi Noto, Atsushi Goto, Tetsuro Tsujimoto, Mitsuhiko Noda, Giuseppe Biondi-Zoccai. Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysisPLoS ONE 2012; 7(3): e33411 doi: 10.1371/journal.pone.0033411
9
Vincent Kaddai, Francesco Negro. Current understanding of insulin resistance in hepatitis CExpert Review of Gastroenterology & Hepatology 2011; 5(4): 503 doi: 10.1586/egh.11.43
10
Qingyun Zhang, Jian Kong, Shuying Dong, Wenlei Xu, Wenbing Sun. Metformin exhibits the anti-proliferation and anti-invasion effects in hepatocellular carcinoma cells after insufficient radiofrequency ablationCancer Cell International 2017; 17(1) doi: 10.1186/s12935-017-0418-6
11
Wei-Hsu Ko, Sherry Yueh-Hsia Chiu, Kuo-Ching Yang, Hsiu-Hsi Chen. Diabetes, hepatitis virus infection and hepatocellular carcinoma: A case-control study in hepatitis endemic areaHepatology Research 2012; 42(8): 774 doi: 10.1111/j.1872-034X.2012.00979.x
12
Chenwi M. Ambe, Amit Mahipal, Jimmy Fulp, Lu Chen, Mokenge P. Malafa, Jose G. Trevino. Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the LiteraturePLOS ONE 2016; 11(3): e0151632 doi: 10.1371/journal.pone.0151632
13
Yonghua Yang. Metformin for cancer preventionFrontiers of Medicine 2011; 5(2): 115 doi: 10.1007/s11684-011-0112-3
14
Weiling Leng, Juan Jiang, Bing Chen, Qinan Wu. Metformin and Malignant Tumors: Not Over the HillDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2021; : 3673 doi: 10.2147/DMSO.S326378
15
Cristina Bosetti, Matteo Franchi, Federica Nicotra, Rosario Asciutto, Luca Merlino, Carlo La Vecchia, Giovanni Corrao. Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databasesPharmacoepidemiology and Drug Safety 2015; 24(7): 771 doi: 10.1002/pds.3801
16
Masahiro Sakata, Akihiko Kawahara, Takumi Kawaguchi, Jun Akiba, Tomoki Taira, Eitaro Taniguchi, Mitsuhiko Abe, Hironori Koga, Masayoshi Kage, Michio Sata. Decreased expression of insulin and increased expression of pancreatic transcription factor PDX-1 in islets in patients with liver cirrhosis: a comparative investigation using human autopsy specimensJournal of Gastroenterology 2013; 48(2): 277 doi: 10.1007/s00535-012-0633-9
17
Wai Gin Lee, Cameron I. Wells, John L. McCall, Rinki Murphy, Lindsay D. Plank. Prevalence of diabetes in liver cirrhosis: A systematic review and meta‐analysisDiabetes/Metabolism Research and Reviews 2019; 35(6) doi: 10.1002/dmrr.3157
18
Takumi Kawaguchi, Takuji Torimura. Impact of insulin resistance on hepatocellular carcinomaKanzo 2015; 56(4): 127 doi: 10.2957/kanzo.56.127
19
Hsin-Hwa Tsai, Hong-Yue Lai, Yueh-Chiu Chen, Chien-Feng Li, Huei-Sheng Huang, Hsiao-Sheng Liu, Yau-Sheng Tsai, Ju-Ming Wang. Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathwayOncotarget 2017; 8(8): 13832 doi: 10.18632/oncotarget.14640
20
Andreas E. Buchs, Barbara G. Silverman. Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort studyMetabolism 2011; 60(10): 1379 doi: 10.1016/j.metabol.2011.05.002
21
Victoria Svop Jensen, Christian Fledelius, Christina Zachodnik, Jesper Damgaard, Helle Nygaard, Kristina Steinicke Tornqvist, Rikke Kaae Kirk, Birgitte Martine Viuff, Erik Max Wulff, Jens Lykkesfeldt, Henning Hvid. Insulin treatment improves liver histopathology and decreases expression of inflammatory and fibrogenic genes in a hyperglycemic, dyslipidemic hamster model of NAFLDJournal of Translational Medicine 2021; 19(1) doi: 10.1186/s12967-021-02729-1
22
Minh Truong Do, Hyung Gyun Kim, Tilak Khanal, Jae Ho Choi, Dong Hee Kim, Tae Cheon Jeong, Hye Gwang Jeong. Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathwaysToxicology and Applied Pharmacology 2013; 271(2): 229 doi: 10.1016/j.taap.2013.05.010
23
Stephen A Harrison, Matthew J Lincoln, Katharine K Roberts. Insulin resistance in chronic hepatitis C: the search for effective drug treatment continuesExpert Review of Gastroenterology & Hepatology 2012; 6(4): 401 doi: 10.1586/egh.12.29
24
Manal M. Hassan, Steven A. Curley, Donghui Li, Ahmed Kaseb, Marta Davila, Eddie K. Abdalla, Milind Javle, Dalia M. Moghazy, Richard D. Lozano, James L. Abbruzzese, Jean-Nicolas Vauthey. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinomaCancer 2010; 116(8): 1938 doi: 10.1002/cncr.24982
25
C. Senthil Kumar, M.D. Raja, D. Sathish Sundar, M. Gover Antoniraj, K. Ruckmani. Hyaluronic acid co-functionalized gold nanoparticle complex for the targeted delivery of metformin in the treatment of liver cancer (HepG2 cells)Carbohydrate Polymers 2015; 128: 63 doi: 10.1016/j.carbpol.2015.04.010
26
Dara Cannata, Yvonne Fierz, Archana Vijayakumar, Derek LeRoith. Type 2 Diabetes and Cancer: What Is the Connection?Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 2010; 77(2): 197 doi: 10.1002/msj.20167
27
E.K.K. Lam, G.D. Batty, R.R. Huxley, A.L.C. Martiniuk, F. Barzi, T.H. Lam, C.M.M. Lawes, G.G. Giles, T. Welborn, H. Ueshima, A. Tamakoshi, J. Woo, H.C. Kim, X. Fang, S. Czernichow, M. Woodward. Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific regionAnnals of Oncology 2011; 22(3): 730 doi: 10.1093/annonc/mdq405
28
S. Bo, A. Benso, M. Durazzo, E. Ghigo. Does use of metformin protect against cancer in Type 2 diabetes mellitus?Journal of Endocrinological Investigation 2012; 35(2): 231 doi: 10.1007/BF03345423
29
Hui-Wen Tseng, Sung-Chou Li, Kuo-Wang Tsai. Metformin Treatment Suppresses Melanoma Cell Growth and Motility Through Modulation of microRNA ExpressionCancers 2019; 11(2): 209 doi: 10.3390/cancers11020209
30
Valter Donadon, Massimiliano Balbi, Giorgio Zanette. Hyperinsulinemia and risk for hepatocellular carcinoma in patients with chronic liver diseases and Type 2 diabetes mellitusExpert Review of Gastroenterology & Hepatology 2009; 3(5): 465 doi: 10.1586/egh.09.41
31
LORENA CASTRO S., GUILLERMO SILVA P.. HÍGADO GRASO NO ALCOHÓLICORevista Médica Clínica Las Condes 2015; 26(5): 600 doi: 10.1016/j.rmclc.2015.09.006
32
Cristóbal Belda-Iniesta, Olga Pernía, Rafael Simó. Metformin: a new option in cancer treatmentClinical and Translational Oncology 2011; 13(6): 363 doi: 10.1007/s12094-011-0669-y
33
Ji-Yeon Lee, Suk-Yong Jang, Chung Mo Nam, Eun Seok Kang. Incident Hepatocellular Carcinoma Risk in Patients Treated with a Sulfonylurea: A Nationwide, Nested, Case-Control StudyScientific Reports 2019; 9(1) doi: 10.1038/s41598-019-44447-1
34
Kavita Bhalla, Bor Jang Hwang, Ruby E. Dewi, William Twaddel, Olga G. Goloubeva, Kwok-Kin Wong, Neeraj K. Saxena, Shyam Biswal, Geoffrey D. Girnun. Metformin Prevents Liver Tumorigenesis by Inhibiting Pathways Driving Hepatic LipogenesisCancer Prevention Research 2012; 5(4): 544 doi: 10.1158/1940-6207.CAPR-11-0228
35
Ehab Abdel-Atti. HCC Burden in EgyptGastroenterology & Hepatology : Open Access 2015; 2(3) doi: 10.15406/ghoa.2015.02.00045
36
Shujuan Ma, Yixiang Zheng, Yanni Xiao, Pengcheng Zhou, Hongzhuan Tan. Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patientsMedicine 2017; 96(19): e6888 doi: 10.1097/MD.0000000000006888
37
Chien-Hsieh Chiang, Chia-Sheng Kuo, Wan-Wan Lin, Jun-Han Su, Jin-De Chen, Kuo-Chin Huang. Chronic Viral Hepatitis Signifies the Association of Premixed Insulin Analogues with Liver Cancer Risks: A Nationwide Population-Based StudyInternational Journal of Environmental Research and Public Health 2019; 16(12): 2097 doi: 10.3390/ijerph16122097
38
M A Pierotti, F Berrino, M Gariboldi, C Melani, A Mogavero, T Negri, P Pasanisi, S Pilotti. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effectsOncogene 2013; 32(12): 1475 doi: 10.1038/onc.2012.181
39
Cristina Margini, Jean F. Dufour. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatmentLiver International 2016; 36(3): 317 doi: 10.1111/liv.13031
40
Harold E. Lebovitz. Malignancy Concerns With Antidiabetic Therapies: Examining the EvidenceEndocrine Practice 2010; 16: 14 doi: 10.1016/S1530-891X(20)42872-1
41
J K Dyson, Q M Anstee, S McPherson. Republished: Non-alcoholic fatty liver disease: a practical approach to treatmentPostgraduate Medical Journal 2015; 91(1072): 92 doi: 10.1136/postgradmedj-2013-100404rep
42
Naim Alkhouri, Arthur McCullough. Obesity, Inflammation and Cancer2013; : 219 doi: 10.1007/978-1-4614-6819-6_9
43
Panagiota Papanagnou, Theodora Stivarou, Maria Tsironi. Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic DrugsPharmaceuticals 2016; 9(2): 24 doi: 10.3390/ph9020024
44
Ryan J O Dowling, Saroj Niraula, Vuk Stambolic, Pamela J Goodwin. Metformin in cancer: translational challengesJournal of Molecular Endocrinology 2012; 48(3): R31 doi: 10.1530/JME-12-0007
45
Sara Gandini, Matteo Puntoni, Brandy M. Heckman-Stoddard, Barbara K. Dunn, Leslie Ford, Andrea DeCensi, Eva Szabo. Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and ConfoundersCancer Prevention Research 2014; 7(9): 867 doi: 10.1158/1940-6207.CAPR-13-0424
46
Ilaria Imarisio, Chiara Paglino, Carlo Ganini, Luigi Magnani, Riccardo Caccialanza, Camillo Porta. The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinomaFuture Oncology 2012; 8(8): 1051 doi: 10.2217/fon.12.74
47
K. H. Williams, N. A. Shackel, M. D. Gorrell, S. V. McLennan, S. M. Twigg. Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic DuoEndocrine Reviews 2013; 34(1): 84 doi: 10.1210/er.2012-1009
48
Navid Sadeghi, James L. Abbruzzese, Sai-Ching J. Yeung, Manal Hassan, Donghui Li. Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic CancerClinical Cancer Research 2012; 18(10): 2905 doi: 10.1158/1078-0432.CCR-11-2994
49
Madhia Shahid, Gabriel Q. Shaibi, Hayley Baines, Pamela Garcia-Filion, Zoe Gonzalez-Garcia, Micah Olson. Risk of hypoglycemia in youth with type 2 diabetes on insulinJournal of Pediatric Endocrinology and Metabolism 2018; 31(6): 625 doi: 10.1515/jpem-2018-0014
50
Andrea DeCensi, Matteo Puntoni, Pamela Goodwin, Massimiliano Cazzaniga, Alessandra Gennari, Bernardo Bonanni, Sara Gandini. Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysisCancer Prevention Research 2010; 3(11): 1451 doi: 10.1158/1940-6207.CAPR-10-0157
51
Guang-Ying Shi, Yu Sun, Xing-Chen Liang, Jing-Dong Xie. Clinical significance of expression of serum insulin-like growth factor-1 in patients with primary liver cancer and diabetes mellitusWorld Chinese Journal of Digestology 2021; 29(5): 236 doi: 10.11569/wcjd.v29.i5.236
Abstract() |  Core Tip() |  Full Article(HTML)() | Times Cited  (0) | Total Visits (0) | Open
52
Sahil Mittal, Donna L. White, Fasiha Kanwal, Norman Sussman, Hashem B. El-Serag. Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatocellular Carcinoma: How Common?Current Hepatology Reports 2015; 14(2): 87 doi: 10.1007/s11901-015-0259-5
53
Wen-Yi Shau, Yu-Yun Shao, Yi-Chun Yeh, Zhong-Zhe Lin, Raymond Kuo, Chih-Hung Hsu, Chiun Hsu, Ann-Lii Cheng, Mei-Shu Lai. Diabetes Mellitus Is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular CarcinomaThe Oncologist 2012; 17(6): 856 doi: 10.1634/theoncologist.2012-0065
54
Cheng-Chieh Lin, Jen-Huai Chiang, Chia-Ing Li, Chiu-Shong Liu, Wen-Yuan Lin, Teng-Fu Hsieh, Tsai-Chung Li. Cancer risks among patients with type 2 diabetes: a 10-year follow-up study of a nationwide population-based cohort in TaiwanBMC Cancer 2014; 14(1) doi: 10.1186/1471-2407-14-381
55
Yu-Wei Chen, Han-Hsiang Chen, Tsang-En Wang, Ching-Wei Chang, Chen-Wang Chang, Wei-Che Chen, Chih-Jen Wu. The dissociation between the diabetes and both Child–Pugh score and in-hospital mortality in cirrhotic patients due to hepatitis B, hepatitis C, or alcoholicHepatology International 2011; 5(4): 955 doi: 10.1007/s12072-011-9274-y
56
Xu Li, Xiaocong Wang, Pujun Gao. Diabetes Mellitus and Risk of Hepatocellular CarcinomaBioMed Research International 2017; 2017: 1 doi: 10.1155/2017/5202684
57
Giovan Giuseppe Di Costanzo, Raffaella Tortora, Filomena Morisco, Luigi Addario, Maria Guarino, Gabriella Cordone, Luigia Falco, Nicola Caporaso. Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular CarcinomaTargeted Oncology 2017; 12(1): 61 doi: 10.1007/s11523-016-0454-5
58
Mervat M. El-Eshmawy, Tharwat S. Kandil, Hala A. Abd El-Hafez, Ahmed Y. Abo El yazid, El Hadidy M. El Hadidy. Type 2 diabetes mellitus is a risk factor for hepatocellular carcinoma in Egyptian patients with HCV-related cirrhosisInternational Journal of Diabetes in Developing Countries 2014; 34(4): 210 doi: 10.1007/s13410-013-0186-3
59
Young Hoon Sul, Myung Sun Lee, Eun Young Cha, Phuong Thien Thuong, Nguyen Minh Khoi, In Sang Song. An <i>ent</i>-Kaurane Diterpenoid from <i>Croton tonkinensis</i> Induces Apoptosis by Regulating AMP-Activated Protein Kinase in SK-HEP1 Human Hepatocellular Carcinoma CellsBiological and Pharmaceutical Bulletin 2013; 36(1): 158 doi: 10.1248/bpb.b12-00873
60
Aparna Bhat, Giada Sebastiani, Mamatha Bhat. Systematic review: Preventive and therapeutic applications of metformin in liver diseaseWorld Journal of Hepatology 2015; 7(12): 1652-1659 doi: 10.4254/wjh.v7.i12.1652
61
Mona A. Abu El Makarem, Mohammed Eslam, Douaa Sayed, Mohamed Shawkat, Naglaa K. Idriss, Elwy M. Soliman, Tahra Sherif, Ragaa Abdelshaheed, Hesham Abdelhailm, Mohamed A. Sahrawi, Sahar Elheney. Diabetes worsening of hepatitis C cirrhosis: Are alterations in monocytic tissue factor (CD 142) is the cause?Annals of Hepatology 2014; 13(1): 27 doi: 10.1016/S1665-2681(19)30901-9
62
Ian N. Hines, Hadley J. Hartwell, Yan Feng, Elizabeth J. Theve, Gregory A. Hall, Sara Hashway, Jessica Connolly, Michelle Fecteau, James G. Fox, Arlin B. Rogers. Insulin Resistance and Metabolic Hepatocarcinogenesis with Parent-of-Origin Effects in A×B MiceThe American Journal of Pathology 2011; 179(6): 2855 doi: 10.1016/j.ajpath.2011.08.014
63
Waihong Chung, Kittichai Promrat, Jack Wands. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseasesWorld Journal of Hepatology 2020; 12(9): 533-557 doi: 10.4254/wjh.v12.i9.533
64
Meei-Shyuan Lee, Chih-Cheng Hsu, Mark L Wahlqvist, Hsin-Ni Tsai, Yu-Hung Chang, Yi-Chen Huang. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individualsBMC Cancer 2011; 11(1) doi: 10.1186/1471-2407-11-20
65
Matthew M. Yeh, Yajuan Liu, Michael Torbenson. Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis: a clinical, pathological, and genetic studyHuman Pathology 2015; 46(11): 1769 doi: 10.1016/j.humpath.2015.07.018
66
Zachary Bloomgarden, Yehuda Handelsman. Cancer mortality and insulin glargineJournal of Diabetes 2009; 1(3): 131 doi: 10.1111/j.1753-0407.2009.00038.x
67
S. R. Lord, N. Patel, D. Liu, J. Fenwick, F. Gleeson, F. Buffa, A. L. Harris. Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer MetabolismJNCI Monographs 2015; 2015(51): 81 doi: 10.1093/jncimonographs/lgv011
68
Ryosuke Tateishi, Koji Uchino, Naoto Fujiwara, Tetsuo Takehara, Takeshi Okanoue, Masataka Seike, Hitoshi Yoshiji, Hiroshi Yatsuhashi, Masahito Shimizu, Takuji Torimura, Mitsuhiko Moriyama, Isao Sakaida, Hiroyuki Okada, Tetsuhiro Chiba, Makoto Chuma, Kazuhiko Nakao, Hajime Isomoto, Yutaka Sasaki, Shuichi Kaneko, Tsutomu Masaki, Kazuaki Chayama, Kazuhiko Koike. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 updateJournal of Gastroenterology 2019; 54(4): 367 doi: 10.1007/s00535-018-1532-5
69
Kira Harris, Lisa Smith. Safety and Efficacy of Metformin in Patients With Type 2 Diabetes Mellitus and Chronic Hepatitis CAnnals of Pharmacotherapy 2013; 47(10): 1348 doi: 10.1177/1060028013503108
70
Stephanie Klein, Jean-François Dufour. Nonalcoholic fatty liver disease and hepatocellular carcinomaHepatic Oncology 2017; 4(3): 83 doi: 10.2217/hep-2017-0013
71
Simona Bo, Anna Castiglione, Ezio Ghigo, Luigi Gentile, Marilena Durazzo, Paolo Cavallo-Perin, Giovannino Ciccone. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patientsEuropean Journal of Endocrinology 2013; 169(1): 117 doi: 10.1530/EJE-13-0299
72
Matthias Evert, Diego F. Calvisi, Katja Evert, Valentina De Murtas, Gioia Gasparetti, Sandra Mattu, Giulia Destefanis, Sara Ladu, Antje Zimmermann, Salvatore Delogu, Sara Thiel, Andrea Thiele, Silvia Ribback, Frank Dombrowski. V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesisHepatology 2012; 55(5): 1473 doi: 10.1002/hep.25600
73
Emmanuel Beck, André J. Scheen. Quels bénéfices antitumoraux attendre de la metformine ?Annales d'Endocrinologie 2013; 74(2): 137 doi: 10.1016/j.ando.2013.02.009
74
Chien-Ming Lin, Hui-Ling Huang, Fang-Ying Chu, Hueng-Chuen Fan, Hung-An Chen, Der-Ming Chu, Li-Wei Wu, Chung-Ching Wang, Wei-Liang Chen, Shih-Hua Lin, Shinn-Ying Ho, Suminori Akiba. Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort StudyPLOS ONE 2015; 10(5): e0125421 doi: 10.1371/journal.pone.0125421
75
Donghui LI. Metformin as an antitumor agent in cancer prevention and treatmentJournal of Diabetes 2011; 3(4): 320 doi: 10.1111/j.1753-0407.2011.00119.x
76
Javier Ampuero, Manuel Romero-Gomez. Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metforminWorld Journal of Hepatology 2015; 7(8): 1105-1111 doi: 10.4254/wjh.v7.i8.1105
77
Siddharth Singh, Preet Paul Singh, Abha Goyal Singh, Mohammad Hassan Murad, William Sanchez. Anti-Diabetic Medications and the Risk of Hepatocellular Cancer: A Systematic Review and Meta-AnalysisAmerican Journal of Gastroenterology 2013; 108(6): 881 doi: 10.1038/ajg.2013.5
78
Yao-Yao Zhou, Gui-Qi Zhu, Tian Liu, Ji-Na Zheng, Zhang Cheng, Tian-Tian Zou, Martin Braddock, Shen-Wen Fu, Ming-Hua Zheng. Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular CarcinomaScientific Reports 2016; 6(1) doi: 10.1038/srep33743
79
Angela Mazza, Barbara Fruci, Giorgia Anna Garinis, Stefania Giuliano, Roberta Malaguarnera, Antonino Belfiore. The Role of Metformin in the Management of NAFLDExperimental Diabetes Research 2012; 2012: 1 doi: 10.1155/2012/716404
80
Takumi Kawaguchi, Dan Nakano, Takuji Torimura. Alcoholic/Non-Alcoholic Digestive Diseases2019; : 65 doi: 10.1007/978-981-13-1465-0_7
81
Harold E. Lebovitz. Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 DiabetesDiabetes Care 2011; 34(Supplement_2): S225 doi: 10.2337/dc11-s225
82
Claudia A. Couto, Claudio L. Gelape, Fernando Calmet, Paul Martin, Cynthia Levy. Effect of Ethnicity on Liver Transplant for Hepatocellular CarcinomaExperimental and Clinical Transplantation 2013; 11(4): 339 doi: 10.6002/ect.2013.0008
83
Run-Ze Shang, Shi-Bin Qu, De-Sheng Wang. Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospectsWorld Journal of Gastroenterology 2016; 22(45): 9933-9943 doi: 10.3748/wjg.v22.i45.9933
84
Bindiya Thakkar, Konstantinos N. Aronis, Maria T. Vamvini, Kelsey Shields, Christos S. Mantzoros. Metformin and Sulfonylureas in Relation to Cancer Risk in Type II Diabetes Patients: A Meta-analysis using primary data of published studiesMetabolism 2013; 62(7): 922 doi: 10.1016/j.metabol.2013.01.014
85
Donna L. White, Fasiha Kanwal, Hashem B. El–Serag. Association Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Systematic ReviewClinical Gastroenterology and Hepatology 2012; 10(12): 1342 doi: 10.1016/j.cgh.2012.10.001
86
J K Dyson, Q M Anstee, S McPherson. Non-alcoholic fatty liver disease: a practical approach to treatmentFrontline Gastroenterology 2014; 5(4): 277 doi: 10.1136/flgastro-2013-100404
87
Shih-Wei Lai, Pei-Chun Chen, Kuan-Fu Liao, Chih-Hsin Muo, Cheng-Chieh Lin, Fung-Chang Sung. Risk of Hepatocellular Carcinoma in Diabetic Patients and Risk Reduction Associated With Anti-Diabetic Therapy: A Population-Based Cohort StudyAmerican Journal of Gastroenterology 2012; 107(1): 46 doi: 10.1038/ajg.2011.384
88
Ian F. Godsland. Insulin resistance and hyperinsulinaemia in the development and progression of cancerClinical Science 2010; 118(5): 315 doi: 10.1042/CS20090399
89
Diana Soffer, Jiaxiao Shi, Joanie Chung, Joanne E Schottinger, Lauren P Wallner, Rowan T Chlebowski, Scott E Lentz, Reina Haque. Metformin and breast and gynecological cancer risk among women with diabetesBMJ Open Diabetes Research & Care 2015; 3(1): e000049 doi: 10.1136/bmjdrc-2014-000049
90
Koji Fujita, Hisakazu Iwama, Hisaaki Miyoshi, Joji Tani, Kyoko Oura, Tomoko Tadokoro, Teppei Sakamoto, Takako Nomura, Asahiro Morishita, Hirohito Yoneyama, Tsutomu Masaki. Diabetes mellitus and metformin in hepatocellular carcinomaWorld Journal of Gastroenterology 2016; 22(27): 6100-6113 doi: 10.3748/wjg.v22.i27.6100
91
Danielle K. DePeralta, Lan Wei, Sarani Ghoshal, Benjamin Schmidt, Gregory Y. Lauwers, Michael Lanuti, Raymond T. Chung, Kenneth K. Tanabe, Bryan C. Fuchs. Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosisCancer 2016; 122(8): 1216 doi: 10.1002/cncr.29912
92
Mamatha Bhat, Akiko Yanagiya, Tyson Graber, Nataliya Razumilava, Steve Bronk, Domenick Zammit, Yunhao Zhao, Chadi Zakaria, Peter Metrakos, Michael Pollak, Nahum Sonenberg, Gregory Gores, Maritza Jaramillo, Masahiro Morita, Tommy Alain. Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cellsOncotarget 2017; 8(31): 50542 doi: 10.18632/oncotarget.10671
93
Valter Donadon, Massimiliano Balbi, Maria Dal Mas, Pietro Casarin, Giorgio Zanette. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver diseaseLiver International 2010; 30(5): 750 doi: 10.1111/j.1478-3231.2010.02223.x
94
Jacob Alexander, Michael Torbenson, Tsung-Teh Wu, Matthew M. Yeh. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: A clinical and pathological studyJournal of Gastroenterology and Hepatology 2013; 28(5): 848 doi: 10.1111/jgh.12116
95
Grace Sun, Sangeeta R. Kashyap. Cancer Risk in Type 2 Diabetes Mellitus: Metabolic Links and Therapeutic ConsiderationsJournal of Nutrition and Metabolism 2011; 2011: 1 doi: 10.1155/2011/708183
96
Takumi Kawaguchi, Eitaro Taniguchi, Yasuyo Morita, Miki Shirachi, Ikuo Tateishi, Eisuke Nagata, Michio Sata. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infectionLiver International 2010; 30(3): 479 doi: 10.1111/j.1478-3231.2009.02191.x
97
Chang-I. Chen, Ching-Feng Kuan, Yu-Ann Fang, Shing-Hwa Liu, Ju-Chi Liu, Li-Li Wu, Chun-Jen Chang, Hsuan-Chia Yang, Jaulang Hwang, James S. Miser, Szu-Yuan Wu. Cancer Risk in HBV Patients With Statin and Metformin UseMedicine 2015; 94(6): e462 doi: 10.1097/MD.0000000000000462
98
Satoko Umetsu, Hiroki Mizukami, Takeshi Saito, Chiaki Uchida, Akiko Igawa, Kazuhiro Kudo, Chieko Itabashi, Sho Osonoi, Guo Danyang, Takanori Sasaki, Soroku Yagihashi, Kenichi Hakamada. Diabetes, an independent poor prognostic factor of non-B non-C hepatocellular carcinoma, correlates with dihydropyrimidinase-like 3 promoter methylationScientific Reports 2020; 10(1) doi: 10.1038/s41598-020-57883-1
99
Chia-Hui LEE, Huang-Meng CHEN, Li-Ke YEH, Meng-Yen HONG, Guewha Steven HUANG. Dosage-dependent Induction of Behavioral Decline in Caenorhabditis elegans by Long-term Treatment of Static Magnetic FieldsJournal of Radiation Research 2012; 53(1): 24 doi: 10.1269/jrr.11057
100
Hui Zhang, Chun Gao, Long Fang, Hong-Chuan Zhao, Shu-Kun Yao. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysisScandinavian Journal of Gastroenterology 2013; 48(1): 78 doi: 10.3109/00365521.2012.719926
101
D. Grahame Hardie. AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancerBiochemical Society Transactions 2011; 39(1): 1 doi: 10.1042/BST0390001
102
Emily M. Ko, Til Stürmer, Jin-Liern Hong, Wendy Camelo Castillo, Victoria Bae-Jump, Michele Jonsson Funk. Metformin and the risk of endometrial cancer: A population-based cohort studyGynecologic Oncology 2015; 136(2): 341 doi: 10.1016/j.ygyno.2014.12.001
103
Ram C. Shankaraiah, Elisa Callegari, Paola Guerriero, Alessandro Rimessi, Paolo Pinton, Laura Gramantieri, Enrico M. Silini, Silvia Sabbioni, Massimo Negrini. Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinomaOncogene 2019; 38(45): 7035 doi: 10.1038/s41388-019-0942-z
104
Etsuko Hashimoto, Katsutoshi Tokushige. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic?Hepatology Research 2012; 42(1): 1 doi: 10.1111/j.1872-034X.2011.00872.x
105
Mohsen Janghorbani, Mohsen Dehghani, Mohammad Salehi-Marzijarani. Systematic Review and Meta-analysis of Insulin Therapy and Risk of CancerHormones and Cancer 2012; 3(4): 137 doi: 10.1007/s12672-012-0112-z
106
Abd Elkhalek Hamed. The association between diabetes and liver disease: The need for a consensusArab Journal of Gastroenterology 2014; 15(3-4): 166 doi: 10.1016/j.ajg.2014.09.002
107
Hui Chen, Yi Xin, Yuting Yang, Fei Li, Guoliang Cheng, Xinxin Zhang. Related Factors and Risk Prediction of Type 2 Diabetes Complicated with Liver Cancer2019 IEEE International Conference on Mechatronics and Automation (ICMA) 2019; : 2138 doi: 10.1109/ICMA.2019.8816301